Functional and Pathological Roles of AHCY

Pedro Vizán1, Luciano Di Croce1,2,3* and Sergi Aranda1**

1 Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain, 2 Universitat Pompeu Fabra (UPF), Barcelona, Spain, 3 Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

Adenosylhomocysteinase (AHCY) is a unique enzyme and one of the most conserved proteins in living organisms. AHCY catalyzes the reversible break of S-adenosylhomocysteine (SAH), the by-product and a potent inhibitor of methyltransferases activity. In mammals, AHCY is the only enzyme capable of performing this reaction. Controlled subcellular localization of AHCY is believed to facilitate local transmethylation reactions, by removing excess of SAH. Accordingly, AHCY is recruited to chromatin during replication and active transcription, correlating with increasing demands for DNA, RNA, and histone methylation. AHCY deletion is embryonic lethal in many organisms (from plants to mammals). In humans, AHCY deficiency is associated with an incurable rare recessive disorder in methionine metabolism. In this review, we focus on the AHCY protein from an evolutionary, biochemical, and functional point of view, and we discuss the most recent, relevant, and controversial contributions to the study of this enzyme.

Keywords: adenosylhomocysteinase, S-adenosylhomocysteine hydrolase, S-adenosylmethionine, gene regulation, epigenetics, chromatin, embryo development

INTRODUCTION

The metabolic enzyme adenosylhomocysteinase (AHCY; also alternatively called SAHH for S-adenosyl-l-homocysteine hydrolase, according to HUGO Gene Nomenclature Committee) is one of the most conserved enzymes in living organisms, including bacteria, nematodes, yeast, plants, insects, and vertebrates (Kusakabe et al., 2015). In mammals, AHCY is the only enzyme that mediates the reversible catalysis of S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine (Turner et al., 1998) (Figure 1). AHCY acts within the one-carbon metabolic cycle, a universal metabolic process that enables the transfer of one-carbon units for biosynthetic processes (purines and thymidine), amino acid homeostasis (cysteine, serine, and methionine), redox cellular control, and epigenetic regulation (Ducker and Rabinowitz, 2017). SAH is the product of S-adenosyl-l-methionine (SAM)-dependent methyltransferases (MTases), which transfers the methyl group from SAM to a variety of cellular substrates, including nucleic acids and proteins.

S-adenosyl-l-methionine is the major methyl donor in the cell and the second most widely used cofactor after ATP (Clarke, 2001; Ye and Tu, 2018). SAH is structurally similar to SAM and binds with a similar range of affinity to the SAM-binding pocket of MTases, thereby inhibiting their activity in a negative feedback loop (Clarke, 2001; Richon et al., 2011; Zhang and Zheng, 2016) (Figure 1). As SAM and SAH compete for the SAM-binding pocket of MTases, the SAM:SAH ratio is considered an indicator of the methylation capacity of cells, and its decrease can correlate with a reduction of the methylation potential (Clarke, 2001; Petrossian and Clarke, 2011).
Unlike acetylation, which only occurs on proteins, methylation can be found at DNA, RNA, and proteins (Clarke, 2001). Chromatin is a macromolecular complex formed by DNA, together with physically associated proteins and non-coding RNAs (Espejo et al., 2020). Nucleosomes are the functional unit of the chromatin and comprise two of each of the core histones H2A, H2B, H3, and H4, which wrap up ~147 base pairs of DNA. Chemical modifications on DNA and histones modulate gene expression and, in some instances, are responsible for conveying the epigenetic information to control cell-type-specific gene expression programs across cell division (Bonasio et al., 2010; Aranda et al., 2015). Indeed, the potential impact of AHCY in controlling methylation of DNA, RNA, and histones has been studied in many model organisms and cell types.

Here, we review the evolutionary conservation of AHCY across living organisms, its enzymatic structure, and its catalysis. We also detail the functional and molecular roles of AHCY in cellular homeostasis in different model organisms. Finally, we discuss the pathogenic influence of AHCY in human disease.

**EVOLUTION, STRUCTURE, AND REGULATION OF ENZYMATIC ACTIVITY OF AHCY**

**Evolution**

Adenosylhomocysteinase is a highly conserved enzyme present in all three major domains: Archaea, Bacteria, and Eukarya (Tehlivets et al., 2013; Kusakabe et al., 2015) (Figure 1). Comprehensive phylogenetic analyses suggest that AHCY evolved from a common ancestor in Archaea and Eukarya, and that orthologs transferred horizontally from these clades to bacteria lineage multiple times during evolution (Bujnicki et al., 2003; Stepkowski et al., 2005). In the absence of AHCY, many bacterial species (e.g., *Escherichia coli*) rely on the 5'-methylthioadenosine/S-adenosylhomocysteine (MTA/SAH) nucleosidase (which is lacking in mammals) for SAH withdrawal (Stepkowski et al., 2005).

The evolutionary reconstruction of the AHCY protein highlights two major divergences in its sequence. First, an insertion of about 40 amino acids is present within the catalytic domain in many bacteria and some eukaryotes, including plants and some pathogens (such as *Plasmodium falciparum*). In contrast, this insertion is absent Archaea and several eukaryotes, including model organisms such as *Dictyostelium discoideum*, *Saccharomyces cerevisiae*, *Caenorhabditis elegans*, and *Drosophila melanogaster*, as well as vertebrates (Bujnicki et al., 2003; Stepkowski et al., 2005). The insertion does not interfere with the folding of the catalytic domain (Tanaka et al., 2004; Reddy et al., 2008), and rodent insert-less AHCY can functionally restore loss-of-function mutants of *Ahcy* (with insertion) in the purple bacteria *Rhodobacter capsulatus* (Aksamit et al., 1995). Of note, in *Arabidopsis thaliana*, specific deletion of this insertion reveals its role in mediating interactions with proteins, such as adenosine kinase and the mRNA cap MTase, as well as the nuclear localization of AHCY, suggesting a regulatory role for this specific insert in plants (Lee et al., 2012).

The second divergent region in AHCY during evolution is a stretch of about eight amino acids in the C-terminal domain present in bacteria and eukaryotes (but not in Archaea), which stabilizes the interaction of AHCY with the NAD⁺ cofactor (Hu et al., 1999; Komoto et al., 2000; Kusakabe et al., 2015). In Archaea, the observed strong affinity for the NAD⁺ cofactor suggests that the lack of a C-terminal tail in AHCY must be replaced by other specific residues (Porcelli et al., 1993).

In eukaryotes, AHCY is among the top 100 most-conserved proteins between yeast and mammals, with about 70% of identity (Mushegian et al., 1998). From zebrafish to humans, AHCY encompasses 10 exons with nearly identical size, indicating that the high conservation in vertebrates is also maintained at a structural genomic level (Zhao et al., 2009). The human genome harbors one AHCY gene in chromosome 20, and 7 pseudogenes in different chromosomes. AHCY is ubiquitously expressed in adult tissues (Chen et al., 2010) and encodes three annotated splicing isoforms (AHCY1 (NP_000678), −2 (NP_001155238), and −3 (NP_001309015), with 432, 404, and 434 amino acids, respectively) that differ only in their first 30 amino acids. These isoforms have not been formally compared side-by-side, although ectopically expressed hAHCY1 mutant lacking the first 14 amino acids accumulates in the nucleus and form catalytically dead tetramers (Grbesa et al., 2017). In-depth molecular and functional analyses are now required to verify and then elucidate a functional regulatory role of this N-terminal region.

**Structure**

Several structures of AHCY have been resolved at an atomic level from bacteria (i.e., *Mycobacterium tuberculosis* and *Pseudomonas aeruginosa*), pathogenic eukaryotes (i.e., *Trypanosoma brucei* and *Plasmodium falciparum*), plants, rodents, and human, all of which share a high structure conservation (Brzezinski, 2020). While some evidence indicates that AHCY can exist in monomeric, homodimeric, and homotetrameric forms within cells (Seo and Ettinger, 1993a,b), all AHCY structures (except that of the plant enzyme *Lupinus luteus*) have been resolved as active homotetramers, with one NAD⁺ cofactor bound in each subunit (Turner et al., 1998; Hu et al., 1999; Brzezinski et al., 2008; Kusakabe et al., 2015). Each monomer comprises three conserved domains (Figure 1): (i) a substrate-binding/catalytic domain (SBD; amino acids [aa] 1–181 and 355–385 in human AHCY); (ii) a NAD cofactor-binding domain (CBD; aa 197–351); and (iii) a C-terminal tail (aa 386–432). Both the SBD and the CBD are connected by two hinge regions (aa 182–196 N-terminal hinge, and 352–354 C-terminal hinge) (Turner et al., 1998; Kusakabe et al., 2015). The central core of the homotetramer is occupied by the cofactor-binding domains from different subunits, and the substrate-binding domains reside at the surface of the tetramer. Notably, the cofactor-binding domain is spatially separated from the substrate-binding domain by a deep cleft in each monomer. The homotetramer is a dimer of dimers, as the C-tail domains from two pairs extend and contact, reciprocally, the NAD-binding domain of the other pair (Turner et al., 1998; Yang et al., 2003; Kusakabe et al.,...
FIGURE 1 | Evolution and structure of adenosylhomocysteinase (AHCY). (A) Scheme of the methionine (Met) metabolic pathway. Enzymes of the pathway are indicated AHCY, methionine adenosyltransferase (MAT), methionine synthase (MS), and SAM-dependent methyltransferase (MTase). MTase transfer a methyl group from SAM to substrates, thereby generating SAH. AHCY breaks SAH into adenosine and homocysteine (Hcy). Hcy can be recycled to methionine (Met) coupled to folate metabolism or to produce glutathione. (B) Selected AHCY amino acid sequences were obtained from Uniprot (https://www.uniprot.org/) using the following accession numbers *Thermotoga maritima* (O51933), *Saccharolobus solfataricus* (P50252), *Archaeoglobus fulgidus* (O28279), *Pseudomonas aeruginosa* (Q9I685), *Plasmodium falciparum* (P50250), *Mycobacterium tuberculosis* (P9WGV3), *Lupinus luteus* (Q9SP37), *Burkholderia pseudomallei* (Q3JY79), *Cytophaga hutchinsonii* (A0A6N4SNR7), *Saccharomyces cerevisiae* (A0A6A5PY71), *Trypanosoma brucei* (Q383X0), *Mus musculus* (P50247), and *Homo sapiens* (P23526). The tree was generated by Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/) and Phylodendron (http://iubioarchive.bio.net/treeapp/treeprint-form.html). The % indicates the similarity with human protein (P23526) calculated using BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The arrow indicates the species where the ~40-amino acid insert is present. (C) The different functional modules of human AHCY are represented. The numbers indicate the position of amino acids. The arrow indicates the position of the divergent insert found in some bacteria and eukaryotes, including plants. Red diamonds indicate the position of the twelve mutations found in patients with AHCY deficiency (R49C, R49H, A50T, T57I, G71S, D86G, A89V, E108K, T112stop, Y143C, V217M, and Y328D). The colored dots indicate the position of posttranslational modifications found in PhosphoSitePlus, with at least five references, and in the literature. (D) Structural model for the human AHCY monomer in the open conformation, the co-factor is depicted in yellow in association with the NAD-binding domain (Protein Data Bank-PDB: 4yvf). The different modules are colored as in (C). (E) Structural model of human AHCY tetrameric enzyme in close conformation (protein data bank-PDB: 3nj4). The different modules are colored as in (C).
the enzymatic reaction as well as the diffusion of substrates (Wang et al., 2005).

**Enzymatic Activity Regulation**

The enzymatic reaction for the reversible catalysis of SAH, first described in 1979 (Palmer and Abeles, 1979), was later supported by analysis of the mammalian structure of AHcy (Kusakabe et al., 2015). At the mechanistic level, AHcy mediates a nucleophilic enzymatic cascade enabled by redox steps (Walsh and Moore, 2019). The reaction is initiated (both via the forward breakup or reverse synthesis of SAH) by an oxidation of SAH or adenosine conjugates by the enzyme-bound NAD^+. The oxidized intermediate is then cleaved to release homocysteine (Hcy) or water (depending on the substrate) and then is subsequently reduced by NADH to form the final product (adenosine or SAH). In thermodynamic equilibrium, the reaction is largely favored toward the synthesis of SAH in vitro, but efficient removal of adenosine and homocysteine enables the net breakup of SAH in vivo (Palmer and Abeles, 1979; Kusakabe et al., 2015; Walsh and Moore, 2019).

Proteomic analysis has revealed that mammalian AHcys are acetylated at lysines 401 and 408 within their C-terminal tail (Choudhary et al., 2009). In vitro, bi-acetylated-K401/408 human AHcy displays a threefold reduction of the catalytic constant and two-fold increase of SAH Km (Wang et al., 2014). Comparative analyses between unmodified and acetylated structures of AHcy indicate a local hydrogen-bound alteration in the vicinity of the modified lysine residues, indicating that slight structural changes in AHcy might have a significant functional impact on its catalytic activity. Two additional modifications, based on the conjugation with short fatty acid derivatives on lysine residues, have recently been reported: the 2-hydroxyisobutyrylation (hib) of lysine (K) 186, and the β-hydroxybutyrylation (bhb) of several lysines (20, 43, 188, 204, 389, and 405) (Huang et al., 2018; Koronowski et al., 2021). In particular, forced K-bhb inhibits AHcy activity in mouse embryonic fibroblast (MEFs) and mouse liver (Koronowski et al., 2021). Enzymatic assays from cells ectopically expressing mutants show that K188R, K389R, and K405R substitutions compromise AHcy activity (Koronowski et al., 2021). In addition to lysine modification, mouse AHcy is posttranslationally modified with a C-terminal β-N-acetylgalactosamine sugar (O-GlcNAcylation) at threonine 136 (Zhu et al., 2020). The oligomerization capacity of AHcy (and therefore, its enzymatic activity) is reduced by mutation of threonine 136 to alanine (T136A), as well as by pharmacological inhibition of glycosylation (Zhu et al., 2020). Importantly, mouse embryonic stem cells (mESCs) expressing AHcy-T136A mutant display a reduced proliferation and low alkaline phosphatase staining (Zhu et al., 2020), suggesting that AHcy glycosylation is important to balance self-renewal and pluripotency in mESCs. Thus, posttranslational modifications in AHcy can impact the structure of the enzyme, thereby modulating its enzymatic activity and its biological role. In line with this, mass spectrometry-based proteomic discovery has revealed an accumulation of other posttranslational modifications (i.e., phosphorylation, acetylation, and ubiquitylation) in the vicinity of the non-catalytic, movable hinge domain and the C-terminal domain (source www.Phosphosite.com) (Figure 1), pointing toward their potential roles as AHcy regulatory domains.

Several resolved AHcy structures contain monovalent cations, which would facilitate the catalytic activity. For instance, the resolved structure of the mouse AHcy has sodium cation allocated in the C-terminal hinge region (Kusakabe et al., 2015), contributing to the recognition of the substrate, similarly as the plant enzyme (Brzezinski et al., 2008). In addition, the AHcy from Pseudomonas aeruginosa binds potassium cations, and kinetic studies indicate that potassium stimulates AHcy enzymatic activity and ligand binding (Czyrko et al., 2018). Conversely, divalent cations, such as zinc and copper, have been shown to inhibit AHcy activity. Structural studies of AHcy from P. aeruginosa indicate that zinc ions are coordinated with AHcy homotetramers near the gate of the active sites, thus preventing its accessibility (Czyrko et al., 2018). Even though a copper ion is not required for its protein stabilization or catalytic activity, AHcy is a strong copper binder both in vitro and in vivo, with a Kd of about $1 \times 10^{-12}$ for free-copper, and Kd of about $1 \times 10^{-17}$ in the presence of EDTA (Bethin et al., 1995; Li et al., 2004). In vitro, copper is a non-competitive inhibitor for the substrates, facilitating the dissociation of NAD^+ in a concentration-dependent manner (Li et al., 2007). Although Cu-AHcy structures have not been resolved, computational predictions as well as the mechanism of inhibition suggest that Cu^2+ binds the central core of the AHcy tetramer, preventing subunit interaction and/or decreasing NAD^+ affinity (Li et al., 2007). Both AHcy’s capacity to bind copper, which is comparable with albumin (Musuoka et al., 1993), and its high abundance in the liver, where it comprises 0.5% of total hepatic cytosome protein (Bethin et al., 1995), indicate that AHcy could contribute significantly to the hepatic copper metabolism and copper-associated human syndromes, such as Wilson disease. All these data suggest that cation-AHcy interaction may have significant relevance and that the biological and pathological cross-talk between AHcy and cations needs further exploration.

In vitro binding experiments have shown that bovine AHcy endows two adenosine binding sites, and their usage depends on the enzyme-bound NAD^+/NADH ratio (Kloor et al., 2003). With a low affinity, adenosine binds the AHcy-NAD^+ at the catalytic domain while, with high affinity, adenosine binds the enzymatically inactive AHcy-NADH at the cofactor domain (Kloor et al., 2003). Despite the importance of NAD^+ as a cofactor, whether an intracellular fluctuation in NAD^+/NADH concentrations influences AHcy activity or its adenosine binding in vivo remains unknown.

**BIOLOGICAL AND FUNCTIONAL ROLES OF AHCY**

**AHcy Function in Embryonic Development**

Considering its strong conservation during evolution and its ability to affect the methylation potential in cells, the functionality of AHcy has been explored in multiple organisms.
The *Arabidopsis thaliana* genome harbors two AHCY paralogs (*AtSAHH1* and *AtSAHH2*) with non-redundant functions. While *AtSAHH2* seems functionally dispensable in plants (Rocha et al., 2005), a loss-of-function mutation in *AtSAHH1* is embryonic lethal and impairs the DNA methylation-dependent gene silencing (Furner et al., 1998). Moreover, genetic and pharmacological reduction of *AtSAHH1* activity results in developmental abnormalities (i.e., slow growth and reduced fertility) (Furner et al., 1998; Rocha et al., 2005; Wu et al., 2009). At the molecular level, *AtSAHH1* mutant plants display a general DNA hypomethylation and alterations in the expression of key developmental genes, a defect attributed to direct inhibition of plant DNA methyltransferases or histone methyltransferases required to sustain genome methylation (Rocha et al., 2005; Mull et al., 2006; Jordan et al., 2007; Ouyang et al., 2012). Similarly, tobacco plants with reduced expression or pharmacological blockade of AHCY show defects in growth and flowering, reduced DNA methylation on repetitive elements, and ectopic expression of genes critical for flower development in different organs (Tanaka et al., 1997; Fulnecek et al., 2011). Finally, the tomato genome contains three related genes encoding for highly conserved SAHH that display functional redundancy, in contrast to those in *A. thaliana* (Li et al., 2015). Simultaneous silencing of all three genes inhibits vegetative growth (Li et al., 2015). Overall, these studies indicate the essentiality of AHCY for proper plant development and growth.

The mouse genome harbors the *Ahc* gene in chromosome 2, and at least five intron-less genomic sequences similar to the complementary DNA (cDNA) in chromosomes X, 1, and 16 (from 86 to 99.7% identity). These latter likely correspond to pseudogenes (based on the alignment of mouse *Ahc* cDNA-CCDS16942.1, using BLAT; Kent, 2002), and at least one (in chr16) encodes for a potentially complete wild-type form of AHCY protein. Phenotypic analysis of a large knockout mouse line collection indicates that homozygous deletion of *Ahc* is embryonic lethal before E9.5 (Dickinson et al., 2016), and chromosomal microdeletions (of about 100 kb) encompassing the *Ahc* gene in mice cause recessive lethality at the blastula stage (Miller et al., 1994). Several pieces of evidence point to the essential role of *Ahc* during early mouse embryo development at the pre-implantation stage. First, during the first 4.5 days post-coitum, *Ahc* expression increases gradually from the zygote to blastula stages, following the acquisition of the pluripotency (Aranda et al., 2019). Second, the pharmacological treatment of mouse embryos with AHCY inhibitors severely compromises the blastula progression (Miller et al., 1994; Aranda et al., 2019). Third, specific depletion of *Ahc* drastically reduces the proliferation of mESCs derived from blastocyst (Aranda et al., 2019), and a prolonged period of *Ahc* depletion promotes spontaneous mESC differentiation (Zhu et al., 2020). Further generation of inducible or tissue-specific AHCY knockout mice models would be of great interest to dissect its role during development or adult tissue homeostasis.

**AHCY Function in Cellular Stress**

Metabolomics analysis of young and old *Drosophila melanogaster* indicates that aging in flies correlates with a remarkable accumulation of SAH. Conversely, fly strains naturally selected for their longevity display reduced levels of SAH (Parkhitko et al., 2016). Reduction of *dAhc* by RNA interference in the whole body or in a neural-specific manner drastically increases SAH levels and reduces lifespan. Conversely, the suppression of two enzymatically inactive paralogs of *dAhc* (*dAHCyL1* and *dAHCyL2*) increase lifespan, presumably because they act as dominant-negative *dAhc* interactors (Parkhitko et al., 2016). In zebrafish, loss-of-function mutations in *Ahc* are lethal, causing defects in exocrine pancreas development (Yee et al., 2005). In addition, mutants display hepatic steatosis (accumulation of lipids in hepatocytes) and liver degeneration early at larval stage (Yee et al., 2005; Matthews et al., 2009), two common features observed in human patients with AHCY deficiency (see below). These studies suggest that AHCY plays a major role in controlling cellular homeostasis and tissue damage in animals. Although the mechanisms underlying increased aging and tissue degeneration in AHCY-deficient animals have not been experimentally determined, they are likely due to: (i) a reduced potential of the transmethylation reaction for specific substrates; (ii) increased oxidative stress, as a consequence of a reduction in the flux homocysteine into the transsulfuration pathway for glutathione production; and/or (iii) replication stress, caused by decreased availability of adenosine for nucleotide production.

In agreement with its potential role in cellular toxicity, a knockdown of AHCY in the hepatocellular carcinoma cell line HepG2 results in attenuation of cell cycle progression and increased DNA damage (Beluzic et al., 2018). The cytotoxic effects can be reversed by adenosine supplementation, thus suggesting that mild inactivation of AHCY may cause cellular stress in liver cells, due to adenosine depletion (Beluzic et al., 2018).

**Molecular Effects on DNA, RNA, and Histone Methylation**

DNA methylation is a well-studied and paradigmatic epigenetic mark (Bonasio et al., 2010). Once deposited, the 5-methylcytosine mark can self-perpetuate by a well-known molecular mechanism, influencing genome functionality. DNA methyltransferase 1 (DNMT1), the enzyme responsible for the maintenance of DNA methylation, recognizes hemimethylated DNA during replication and establishes the methyl group in the newly synthesized DNA (Bonasio et al., 2010). This process is assisted by several accessory proteins, including the multidomain protein UHRF1 (Blanchart et al., 2018). In a proteomic survey during the cell cycle of HeLa cells, AHCY was found as a partner of DNMT1 methyltransferase (Zhou et al., 2018). This interaction was further studied using pull-down approaches and co-immunoprecipitation experiments, showing that AHCY interacts with DNMT1 in vivo (Zhou et al., 2018). These studies suggest that AHCY may play a role in DNA methylation, possibly functioning as a regulator of the DNMT1-mediated reaction.

**AHCY is a rate-limiting factor for DNA methylation maintenance**

AHCY is a rate-limiting factor for DNA methylation maintenance, its role during epigenomic reprogramming throughout embryo development and/or in disease progression, such as cancer, must now be investigated. In addition to maintaining DNA methylation, AHCY also exerts a role in regulating *de novo* DNA methylation (Zhou et al., 2018).
et al., 2015). This role is proposed to be mediated throughout the AHCY inhibition by the developmentally regulated long non-coding RNA H19. In vitro, U-rich nucleotide elements present in H19 reduce the ability of recombinant AHCY to breakdown SAH in vitro (Zhou et al., 2015). In vivo, knockdown of H19 increases the cellular activity of AHCY in myotubes differentiated from mouse myoblasts. As a consequence, H19 knockdown induces extensive changes in the pattern of genome methylation in myotubes, with specific DNMT3B-target genes gaining DNA methylation in an AHCY-dependent manner. Overall, this indicates that, consistent with its function, AHCY deficiency impacts both in DNA methylation maintenance as well as in de novo methylation, thus profoundly influencing the epigenome of cells (Figure 2).

RNA methyltransferases are highly sensitive to the reduction of the SAM:SAH ratio (Clarke, 2001). Indeed, pharmacological treatment with 3-deazaadenosine, a specific AHCY inhibitor, induces reduction of methyl RNA levels in mouse macrophage and osteosarcoma cells, including loss of the N6-methyladenosine (m6A) (Backlund et al., 1986). In mouse embryonic fibroblasts, this m6A reduction upon AHCY inhibition is functionally linked to a delay in processing RNAs from circadian rhythm genes, thus impacting their oscillatory behavior response (Fustin et al., 2013). Extending this observation, Fustin et al. (2020) have recently found that targeting AHCY activity with 3-deazaneplanocin A (DZnep) produces a loss in the oscillatory transcriptional response of circadian-associated genes in different organisms (from unicellular algae to humans). The loss of the oscillatory transcriptional activation of the Hes7 gene during somitogenesis on DZnep-treated mouse embryos suggests that methylation flux, directed by AHCY, is a universal regulator of biological circadian rhythms in metazoans (Fustin et al., 2020).

Global steady-state levels of cap methylation on mRNA (7-methylguanosine, m7G) are seemingly unaffected upon AHCY inhibition in mouse embryonic fibroblasts (measured as the ratio m7G methylated/unmethylated mRNA) (Fustin et al., 2013). However, considering the tight association of m7G with mRNA stability, the uncapping of pre-mRNA could be linked with an increase in pre-mRNA degradation, and, therefore, the impact of AHCY inhibition in m7G regulation might be overlooked. Indeed, several experimental evidences show that increased m7G demands are dependent on AHCY functionality in some instances. In developing Xenopus, xAHCY, which remains nearly cytosolic until the blastula stage, starts to accumulate in the nucleus of differentiating cells, which experience a boost in transcriptional activity during gastrulation (Radomski et al., 1999). In Xenopus oocytes, xAHCY displays a nuclear accumulation on active transcribing loops on lampbrush chromosomes (Radomski et al., 1999, 2002) and interacts with mRNA (guanine-7-) methyltransferase through its proximal N-terminal region (Radomski et al., 2002). Furthermore, its pharmacological inhibition compromises both methylation and synthesis of nuclear RNA (Radomski et al., 1999, 2002). Similarly, in human and murine cells, an increased demand for m7G induced upon MYC activation depends on AHCY activity (Fernandez-Sanchez et al., 2015).
et al., 2009). Upon AHCY knockdown, the MYC-induced m7G is compromised and correlates with reduction in Myc-induced core effects in protein synthesis, cell proliferation, and transformation. Interestingly, AHCY is a direct MYC target and it is transcriptionally upregulated in an MYC-dependent manner in numerous cell types (Fernandez-Sanchez et al., 2009). Thus, AHCY appears to be a key response molecule in controlling the molecular and functional effects of Myc.

Based on its role on controlling RNA methylation, AHCY has been long considered a target for antiviral strategies (Bader et al., 1978; De Fazio et al., 1990; Snoeck et al., 1993; Masuta et al., 1995; Daelemans et al., 1997; Chiang, 1998; Daelemans et al., 1998; Huggins et al., 1999; Bray et al., 2000; De Clercq, 2005, 2015; Yoon et al., 2019; Shin et al., 2020). The antiviral properties of AHCY inhibition are based on the metabolic accumulation of SAH, which directly inhibits viral or host RNA MTases required for successful viral spreading (Daelemans et al., 1995; Daelemans et al., 1997; Chiang, 1998; Daelemans et al., 1998; Huggins et al., 1999; Bray et al., 2000; De Clercq, 2005, 2015; Liu and Kiledjian, 2006; Leyssen et al., 2008). AHCY inhibitory compounds show a broad-spectrum antiviral activity against RNA viruses, including rhabdo-, filo-, arena-, paramyxo-, reo-, and retroviruses. In vivo efficacy of AHCY inhibitors is remarkable, as a single dose of either of the three distinct AHCY inhibitors 3-deazaneplanocin A, 3-deazaaristeromycin, or 3-deazaadenosine protects mice against a lethal infection of the Ebola virus (subtype Zaire) (Huggins et al., 1999; Bray et al., 2000, 2002). Recently, the list of AHCY-sensitive viruses has increased, as the novel potent AHCY inhibitors of 6′-fluorinatedaristeromycin analogs have notable activity against emerging positive-stranded RNA (+RNA) viruses, such as the severe acute respiratory syndrome coronavirus (SARS-CoV1), Middle East respiratory syndrome coronavirus (MERS-CoV), chikungunya virus (CHIKV), and Zika virus (ZIKV) (Yoon et al., 2019; Shin et al., 2020). These results have placed 6′-fluorinatedaristeromycin as a drug candidate against COVID-19.

The methylation of core nucleosome histones, which are the most abundant eukaryotic nuclear proteins, influences protein–protein interactions, chromatin structure, and gene expression (Espejo et al., 2020). The potential role of the nucleosome as a SAM consumer is high, as methylation of ~0.1% of all histone residues can consume the complete cellular SAM pool in mammalian cells (Ye and Tu, 2018). Arginines and lysines can be extensively methylated on histone proteins, with the histone 3 lysines 4, 9, 27, 36, and 79 (H3K4, H3K9, H3K27, H3K36, and H3K79, respectively) being the most well-characterized (Zhao and Garcia, 2015). Among the different potential effects of AHCY blockade over histone methylation, the global and local di- and tri-methylation of lysine 4 on histone H3 (H3K4me2/5) appears the most sensitive (Fustin et al., 2013; Greco et al., 2020; Zhu et al., 2020). Recently, Greco et al. (2020) found that the oscillatory increase of H3K4me3 in circadian rhythm-related genes is compromised after pharmacological inhibition of AHCY in mouse embryonic fibroblasts. At the molecular level, AHCY interacts with BMAL1, a key circadian transcription factor, and regulates the oscillatory recruitment of BMAL1 to chromatin, thus impacting the amplitude of the transcriptional oscillations of circadian rhythm-related genes (Greco et al., 2020) (Figure 2). The authors suggest that the dimer AHCY-BMAL1 cooperates with histone methyltransferases for gene activation and that AHCY removes excess of SAH to facilitate local histone methylation demands during the transcription peaks.

**IMPACT OF AHCY IN HUMAN DISEASES**

**AHCY Involvement on Rare Metabolic Disorders**

Wilson disease (WD) is a rare, inborn disorder with severe hepatic and neurological dysfunctions due to the pathological accumulation of copper (Czlonkowska et al., 2018). The clinical symptomatology in WD is highly variable for age of onset (ranging from 5 to 35 years) and severity, varying from nearly asymptomatic with mild changes in personality to acute liver failure or parkinsonian-like effects. Although over 300 disease-causing mutations have been reported in the copper transporter ATP7B, the genotype–phenotype correlation in WD is very poor (Czlonkowska et al., 2018). This suggests the existence of other genetic risk factors influencing WD. As AHCY is a strong copper binder, and copper inhibits AHCY activity in a dose-dependent and non-competitive manner (see above), a pathological link between copper accumulation and the inhibition of AHCY has been proposed. Indeed, the pathological accumulation of copper in the Jackson toxic milk mutant mice (tx-J), which carry a missense mutation in the Atp7b gene, reduces AHCY expression (Bethin et al., 1995; Li et al., 2004, 2007). In this WD murine model, deficit in AHCY associates with an increase of SAH levels, reduction in the SAM:SAH ratio, and DNA hypomethylation (Medici et al., 2013, 2014, 2016). Interestingly, feeding tx-J mice with diets supplemented with betaine or choline normalizes the SAM:SAH ratio, global DNA hypomethylation, and the expression of hepatic genes related to methionine homeostasis (Medici et al., 2013, 2014, 2016). These data provide a link between hepatic copper accumulation and the function on AHCY in the liver.

In humans, at least 204 missense AHCY variants are annotated in public databases1 or reported in the literature. Twelve of these variants are linked with a rare autosomal recessive disorder in the methionine metabolism of hypermethioninemia (R49C, R49H, A50T, T57I, G71S, D86G, E108K, T112stop, Y143C, V217M, and Y328D), characterized by a deficiency of AHCY (OMIM: 180960) (Baric et al., 2004, 2005; Buist et al., 2006; Vugrek et al., 2009; Honzik et al., 2012; Stender et al., 2015; Strauss et al., 2015; Vivante et al., 2017; Bas et al., 2020; Grudzinska Pechhacker et al., 2020). Patients typically display severe hepatic, muscle, and cognitive dysfunction, including multiorgan failure followed by death soon after birth (Tehlivets et al., 2013; Stender et al., 2015; Judkins et al., 2018). In addition to this most frequent and severe version, a mild version of the disease has been reported in one family, who remain nearly asymptomatic during childhood but presented severe hepatic disorders during adulthood (Stender et al., 2015). Dietary interventions that reduce methionine uptake have shown variable benefits for patients, questioning its therapeutic advantage in

---

1https://gnomad.broadinstitute.org/
AHCY deficiency syndrome. For one 40-month-old child for whom dietary therapy was ineffective, liver transplantation restored metabolic parameters and reversed psychomotor and cognitive deficits after 6 months (Strauss et al., 2015). However, the lack of further assessment on the course of the disease, and the difficulties of finding a rapidly compatible donor soon after diagnosis, would argue against liver transplantation as a general indication for AHCY deficiency. Thus, finding an effective therapy is urgently needed for treating AHCY deficiency.

Role of AHCY in Cancer

Adenosylhomocysteinase was initially defined as a tumor suppressor (Leal et al., 2008). In agreement, AHCY-deficient mouse embryonic fibroblasts have a higher proliferative capacity and the ability to escape from replicative senescence (Leal et al., 2008). At a mechanistic level, an AHCY knockdown overcomes the p53-induced cell cycle arrest and abrogates p53-dependent transcriptional activity (Leal et al., 2008). In agreement with a tumor suppressor role, AHCY mRNA expression was found to be reduced in a large number of different solid tumor samples as compared with non-tumor paired tissue (Leal et al., 2008).

However, AHCY’s function as a tumor suppressor seems to be cell type specific, as AHCY inhibition is also linked to anti-migratory and anti-invasive activity in breast cancer cells (Kim et al., 2013; Park et al., 2015) and to enhanced apoptosis in high aggressive neuroblastoma (Westermann et al., 2008; Chayka et al., 2015). In neuroblastoma, AHCY expression is elevated in MYCN-amplified tumor samples and neuroblastoma cell lines (Westermann et al., 2008; Chayka et al., 2015). Interestingly, AHCY knockdown or drug-mediated inhibition induces an increase in apoptosis specifically on MYCN-amplified neuroblast cells (Chayka et al., 2015), thus showing a specific synthetic lethality and making AHCY inhibition a promising therapeutic possibility for personalized treatment of high-risk neuroblastoma.

CONCLUSION

Methylation is one of the most ubiquitous chemical reactions in living organisms (Clarke, 2001). While some methyltransferases retain most of their activity at different SAM:SAH ratios, such as the glycine N-methyltransferase, others are more susceptible to SAH elevation, including tRNA or arginine methyltransferases (Clarke, 2001; Richon et al., 2011; Zhang and Zheng, 2016). Thus, considering the large number of SAM-dependent MTases, which account for nearly 1% of the human protein-coding genes (∼200), their different functionalities, and their distinct sensitivity to SAH accumulation (Clarke, 2001; Petrossian and Clarke, 2011; Richon et al., 2011; Zhang and Zheng, 2016), it is difficult to foresee which is the most relevant methyltransferase affected upon AHCY inhibition. Thus, after AHCY blockade, the influence of one molecular outcome (e.g., loss of DNA methylation, RNA methylation, or protein methylation) in a particular molecular process will depend very much on the following: (i) the biological context (e.g., cell type, stimulus); (ii) the molecular event involved in this biological process (e.g., transcription); (iii) the most relevant methyltransferase involved; and (iv) their relative sensitivity to SAH accumulation.

Also, as the result of the AHCY activity, the methionine cycle can supply the production of adenosine for nucleotide biosynthesis and for homocysteine, the precursor for the biosynthesis of glutathione in higher eukaryotes (Ye and Tu, 2018). Therefore, in addition to increasing the methylation potential, SAH turnover could be essential to cope with replicative-associated oxidative stress, thus expanding the repertoire of the biological process where AHCY plays a role.

Methylations occur in all subcellular compartments. The intracellular concentrations of SAM (∼10 μM) is at the range of the Km of the SAM-dependent MTases, but it can fluctuate 10–100-fold in normal physiological conditions (Clarke, 2001; Ye and Tu, 2018). The nuclear heterogeneity at the transcriptional level and during replication, as well as the existence of phase-separated membrane-less subnuclear compartments (Erdel and Rippe, 2018), likely produce large differences in local fluxes of SAH due to localized transmethylation reactions, such as DNA methylation maintenance at replication sites, or mRNA cap methylation at transcriptionally active chromatin regions (Espajo et al., 2020). Hence, the local recruitment of AHCY seems required to sustain effective transmethylation reactions in time and space. We and others have found that AHCY is recruited to chromatin at specific sites (Aranda et al., 2019; Greco et al., 2020). Our recent discoveries unveil a novel chromatin function of AHCY in controlling gene expression, which is in line with recent data identifying the association of other metabolic enzymes with chromatin (Li et al., 2018). However, our discoveries also present new questions at the mechanistic level: How is AHCY recruited to specific chromatin regions in mammals? How does AHCY control local gene expression? Further studies on protein–protein interactions within chromatin will clarify the molecular mechanisms underlying AHCY’s role in gene regulation. This research direction might also have an impact in AHCY-related pathologies as changes in the nucleocytoplasmic distribution have been reported in several pathological AHCY variants (Grbesa et al., 2017). Therefore, the potential pathogenicity caused by mutants that cause aberrant nuclear localization of AHCY might be linked with its chromatin-related functions.

Hundreds of missense polymorphisms are present in the human AHCY gene across the population (see text footnote 1), some of which have a similar allelic frequency as those identified as pathological variants. This, together with the asymptomatic evolution of some patients with defects in AHCY activity until fertile adulthood (Stender et al., 2015), suggest that AHCY deficiency could be underdiagnosed, and that the impact of AHCY in human pathologies could be underestimated in the general population.

In 2004, AHCY deficiency was first identified in a 5-month-old Croatian infant with delayed psychomotor development, hypotonia, attention defects, and poor head control since birth, who also presented with elevated levels of aminotransferase, methionine, SAH, and SAM in serum (Baric et al., 2004). Since then, additional patients harboring AHCY mutations have been described with similar clinical traits. However, only few associated mutations have been characterized at the molecular
level. In addition to the pathological variants that strongly affect AHCY activity, non-pathologic polymorphic isoforms of AHCY found in different populations display reduced thermal stability of the protein and enzymatic activity (Fumic et al., 2007). More recently, genetic variations of AHCY have been linked to different prognosis of children with neuroblastoma (Novak et al., 2016), thus providing evidence of the potential use of AHCY variants as a molecular biomarker. Considering the pleiotropic effects of AHCY, timely identification of AHCY deficiency may allow for targeted intervention to hinder the progression of related diseases. A systematic analysis of all potentially deficient AHCY variants would provide molecular tools for genetic counseling, as well as for improving the prediction, diagnosis, and clinical outcome of AHCY deficiencies.

The aggressiveness of neuroblastoma cancer subtypes seems to rely on AHCY functionality (Westermann et al., 2008; Chayka et al., 2015). This exciting result places AHCY inhibitors as potential agents to target metabolic dependencies in some cancer types. Supporting this notion, tumor-initiating cells from non-small-cell lung cancer (NSCLC) adenocarcinoma display metabolic reprogramming and rely on methionine to fuel their tumorigenicity (Wang et al., 2019). Interestingly, pharmacological alterations of the methionine cycle, by blocking AHCY with a specific inhibitor, reduce the colony- and tumor-forming abilities of tumor-initiating cells (Wang et al., 2019). Understanding the basis of AHCY-directed metabolic alternations is therefore essential to gain insights into the sensitivity of specific cancer types to therapeutic interventions based on AHCY inhibition and is a prerequisite for developing effective therapies.

**AUTHOR CONTRIBUTIONS**

SA wrote the manuscript and created the figures, together with PV and LD. All authors contributed to the article and approved the submitted version.

**FUNDING**

LD was supported by grants from the Spanish Economy, Industry and Competitiveness (MEIC) (PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR. SA was funded by Ramón y Cajal Program MICIU-FSE (RYC2018-025002-I) and ISCIII-FEDER (PI19/01814). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya.

**ACKNOWLEDGMENTS**

We thank Isabel Espejo for helpful discussions and V. A. Raker for scientific editing.

**REFERENCES**

Aksamit, R. R., Buggay, J. J., and Bauer, C. E. (1995). Expression of rat liver AdoHcy hydrolase in a Rhodobacter capsulatus ahcY mutant restores pigment formation and photosynthetic growth. Biochem. Biophys. Res. Commun. 207, 265–272. doi: 10.1006/bbrc.1995.1182

Aranda, S., Alcaine-Colet, A., Blanco, E., Borras, E., Caillot, C., Sabido, E., et al. (2019). Chromatin capture links the metabolic enzyme AHCY to stem cell proliferation. Sci. Adv. 5:eava2438. doi: 10.1126/sciadv.aava2438

Aranda, S., Mas, G., and Di Croce, L. (2015). Regulation of gene transcription by Polycomb proteins. Sci. Adv. 1:e1500737. doi: 10.1126/sciadv.1500737

Backlund, P. S., Jr., Caridi, D., and Cantoni, G. L. (1986). Effects of the S-adenosylhomocysteine hydrolase inhibitors 3-deazaadenosine and 3-deazauracil on RNA methylation and synthesis. Eur. J. Biochem. 160, 245–251. doi: 10.1111/j.1432-1033.1986.tb09963.x

Bader, J. P., Brown, N. R., Chiang, P. K., and Cantoni, G. L. (2003). Structure, evolution, and inhibitor interaction of S-adenosyl-L-homocysteine hydrolase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 60, 671–673. doi: 10.1107/s1744309108017703

Beluzic, L., Grbesa, I., Beluzic, R., Park, J. H., Kong, H. K., Kopjar, N., et al. (2018). Knock-down of AHCY and depletion of adenosine induces DNA damage and cell cycle arrest. Sci. Rep. 8:40102.

Bethin, K. E., Petrovic, N., and Ettinger, M. J. (1995). Identification of a major hepatic copper binding protein as S-adenosylhomocysteine hydrolase. J. Biol. Chem. 270, 20698–20702. doi: 10.1074/jbc.270.35.20698

Blanchart, A., Navis, A. C., Assafie-Lopes, N., Uososkin, D., Aranda, S., Sontheimer, J., et al. (2018). UHRF1 licensed self-renewal of active neural stem cells. eLife 7:ea1500737. doi: 10.1126/sciadv.1500737

Bonasio, R., Tu, S., and Reinberg, D. (2010). Molecular signals of epigenetic states. Science 330, 616–616. doi: 10.1126/science.1191078

Bray, M., Driscoll, J., and Huggins, J. W. (2000). Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antivir. Res. 45, 135–147. doi: 10.1016/s0166-3542(00)00066-8

Bray, M., Raymond, J. L., Geisbert, T., and Baker, R. O. (2002). 3-deazaneplanocin a induces massively increased interferon-alpha production in Ebola virus-infected mice. Antivir. Res. 55, 151–159. doi: 10.1016/s0166-3542(02)00018-9

Brzezinski, K. (2020). S-adenosyl-L-homocysteine Hydrolase: a structural perspective on the enzyme with two rossmann-fold domains. Biomolecules 10:1682. doi: 10.3390/biom10121682

Brzezinski, K., Bujacz, G., and Jaskolski, M. (2008). Purification, crystallization and preliminary crystallographic studies of plant S-adenosyl-L-homocysteine hydrolase (Lupinus luteus). Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 64, 671–673. doi: 10.1107/s1744309108017703

Buist, N. R., Glenn, B., Vugrek, O., Wagner, C., Stabler, S., Allen, R. H., et al. (2006). S-adenosylhomocysteine hydrolase deficiency in a 26-year-old man. J. Inherit. Metab. Dis. 29, 538–545. doi: 10.1016/j.injme.2005.06.0240-0

Bujnicki, J. M., Prigge, S. T., Caridi, D., and Chiang, P. K. (2003). Structure, evolution, and inhibitor interaction of S-adenosyl-L-homocysteine hydrolase from Plasmodium falciparum. Proteins 52, 624–632. doi: 10.1002/prot.10446
Chayka, O., D’acunto, C. W., Middleton, O., Arab, M., and Sala, A. (2015). Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastoma tumor cells. *J. Biol. Chem.* 290, 2198–2212. doi: 10.1074/jbc.m114.620556

Chen, N. C., Yang, F., Capecci, L. M., Gu, Z., Sacher, A. L., Durante, W., et al. (2010). Regulation of homocysteine metabolism and methylation in human and mouse tissues. *FASEB J.* 24, 2804–2817. doi: 10.1096/fj.09-143651

Chiang, P. K. (1998). Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. *Pharmacol. Ther.* 77, 115–134. doi: 10.1016/s1053-8119(97)00089-2

Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science* 325, 843–840. doi: 10.1126/science.1173571

Clarke, S. (2001). “S-adenosylmethionine-dependent methyltransferases,” in *Homocysteine in Health and Disease*, eds R. Carmel, and D. W. Jackobsen, (Cambridge: Cambridge University Press).

Cłonkowska, A., Litwin, T., Dusek, P., Ferenci, P., Lutsenko, S., Medici, V., et al. (2018). Wilson disease. *Nat. Rev. Dis. Primers* 4:21.

Czyrko, J., Sliwiak, J., Imioczyk, B., Gdaniec, Z., Jaskolski, M., and Brzezinski, K. (2018). Metal-cation regulation of enzyme dynamics is a key factor influencing the activity of S-adenosyl-L-homocysteine hydrolase from *Pseudomonas aeruginosa*. *Sci. Rep.* 8:11334.

Daelemans, D., Este, J. A., Witvrouw, M., Pannecongo, C., Jonckheere, H., and Aquaro, S. (1997). S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation. *Mol. Pharmacol.* 52, 1157–1163. doi: 10.1124/mol.52.6.1157

Daelemans, D., Vandamme, A. M., Shuto, S., Matsuda, A., and De Clercq, E. (2015). Curious discoveries in antiviral drug development: the role of the circadian clock and chromatin remodeling. *Sci. Adv.* 1:11334.

Furner, I. J., Sheikh, M. A., and Collett, C. E. (1998). Gene silencing and Fustin, J. M., Doi, M., Yamaguchi, Y., Hida, H., Nishimura, S., Yoshida, M., et al. (2013). RNA-methylation-dependent RNA processing controls the speed of the circadian clock. *Cell* 155, 793–806. doi: 10.1016/j.cell.2013.10.026

Fustin, J. M., Doi, M., Yamaguchi, Y., Hida, H., Nishimura, S., Yoshida, M., et al. (2020). Methylation deficiency disrupts biological rhythms from bacteria to humans. *Commun. Biol.* 3:211.

Furbeta, L., Kalo, A., Beluzius, R., Kovacevic, L., Lepur, A., Rokic, F., et al. (2017). Mutations in S-adenosylhomocysteine hydrolase (AHCY) affect its nucleocytoplasmic distribution and capability to interact with S-adenosylhomocysteine hydrolase-like 1 protein. *Eur. J. Cell Biol.* 96, 579–590. doi: 10.1016/j.ejcb.2017.05.002

Greco, C. M., Cervantes, M., Fustin, J. M., Ito, K., Ceglia, N., Samad, M., et al. (2020). S-adenosyl-l-homocysteine hydrolase links methionine metabolism to the circadian clock and chromatin remodeling. *Sci. Adv.* 6:eabc5629. doi: 10.1126/sciadv.abc5629

Grudzinska Pechhacker, M. K., Di Scipio, M., Vig, A., Tumber, A., Roslin, N., Tavares, E., et al. (2020). CRBl-related retinopathy overlapping the ocular phenotype of S-adenosylhomocysteine hydrolase deficiency. *Ophthalmic Genet.* 41, 457–464. doi: 10.1080/13816810.2019.1790013

Hoñzik, T., Magnier, J., Krijt, J., Sokolova, J., Yugrek, O., Beluzius, R., et al. (2012). Clinical picture of S-adenosylhomocysteine hydrolase deficiency resembles phosphomannomutase 2 deficiency. *Mol. Genet. Metab.* 107, 611–613. doi: 10.1016/j.ymgme.2012.08.014

Hu, Y., Komoto, J., Huang, Y., Gomi, T., Ogawa, H., Takata, Y., et al. (1999). Structural study of S-adenosylhomocysteine hydrolase from rat liver. *Biochemistry* 38, 8323–8333. doi: 10.1021/bi990332k

Huang, H., Luo, Z., Qi, S., Huang, J., Xu, P., Wang, X., et al. (2018). Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation pathway. *Cell Res.* 28, 111–125. doi: 10.1038/s41422-017-0049.

Huggins, J., Zhang, Z. X., and Bray, M. (1999). Antiviral drug therapy of filovirus infections: s-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. *J. Infect. Dis.* 179(Suppl. 1), S240–S247.

Jordaan, N. D., West, J. P., Bottley, A., Sheikh, M., and Furner, I. (2007). Transcript profiling of the hypomethylated h3gi1 mutant of Arabidopsis. *Plant Mol. Biol.* 65, 571–586. doi: 10.1007/s11103-007-9221-4

Judkins, A. J., Macqueen, B. C., Christensen, R. D., Comstock, J., Mao, R., and Flores-Daubob, J. (2018). Non-immune hydros, hypotonia, encephalopathy, and liver failure with novel compound heterozygous AHCY mutations. *Neonatology* 114, 337–340. doi: 10.1159/000489292.

Kent, W. J. (2002). BLAT—the BLAST-like alignment tool. *Genome Res.* 12, 656–664. doi: 10.1101/gr.229202.

Kim, J. H., Kim, J. H., Kim, S. C., Yi, Y. S., Yang, W. S., Yang, Y., et al. (2013). Adenosine didehydro suppresses MMP-9-mediated invasion of cancer cells by blocking the Ral/Raf-1/ERK/AP-1 signaling pathway. *Biochem. Pharmacol.* 86, 1285–1300. doi: 10.1016/j.bcp.2013.08.022

Kloor, D., Ludtke, A., Stoeva, S., and Osswald, H. (2003). Adenosine binding sites at S-adenosylhomocysteine hydrolase are controlled by the NAAD+/NADH ratio of the enzyme. *Biochemistry* 42, 2194–2202. doi: 10.1021/bi034525x

Kusakabe, Y., Ishihara, M., Umeda, T., Kuroda, D., Nakanishi, M., Kitade, Y., et al. (2000). Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastoma tumor cells. *J. Biol. Chem.* 275, 231–248. doi: 10.1074/jbc.M10725200

Koronowski, K. B., Greco, C. M., Huang, H., Kim, J.-K., Fribourgh, J. L., Crosby, L., et al. (2021). Ketogenesis impact on liver metabolism revealed by proteomics profiling of the hypomethylated h3gi1 mutant of Arabidopsis. *Mol. Genet. Metab.* 139, 1–12. doi: 10.1016/j.ymgme.2020.09.017

Lee, S., Dooxey, A. C., Mcconkey, B. J., and Moffatt, B. A. (2012). Nuclear targeting of methyl-recycling enzymes in *Arabidopsis thaliana* is mediated by specific DNA sequence interactions. *Mol. Plant* 5, 231–248. doi: 10.1093/mp/pss083

Leyesaet, P., De Clercq, E., and Neys, J. (2008). Molecular strategies to inhibit the replication of RNA viruses. *Antivir. Res.* 78, 9–25. doi: 10.1016/j.antiviral.2008.01.004
Parkhitko, A. A., Binari, R., Zhang, N., Asara, J. M., Demontis, F., and Perrimon, N. (2016). Tissue-specific down-regulation of S-adenosyl-homocysteine via suppression of dAchy/L/dAchy/L2 extends heart span and life span in Drosophila. Genes Dev. 30, 1409–1422. doi: 10.1101/gad.282277.116

Petrossian, T. C., and Clarke, S. G. (2011). Uncovering the human Reuters. Mol. Cell Proteomics 10:S11000976.

Ponnaluri, V. K. C., Esteve, P. O., Ruse, C. L. and Pradhan, S. (2018). S-adenosylhomocysteine hydrolyse participates in DNA methylation inheritance. J. Mol. Biol. 430, 2051–2065. doi: 10.1016/j.jmb.2018.05.014

Porcelli, M., Cacciapuoti, G., Fusco, S., Iacomino, G., Gambacorta, A., De Rosa, M., et al. (1993). S-adenosylhomocysteine hydrolyse from the thermophilic archaeon Sulfolobus solfataricus: purification, physico-chemical and immunological properties. Biochim. Biophys. Acta 1164, 179–188. doi: 10.1016/0167-4889(93)90246-n

Radomska, N., Barreto, G., Kaufmann, C., Yokoska, J., Mizumoto, K., and Dreyer, C. (2002). Interaction of S-adenosylhomocysteine hydrolyse of Xenopus laevis with mRNA(adenine-7)-methyltransferase: implication on its nuclear compartmentalisation and on cap methylation of hRNA. Biochim. Biophys. Acta. 1590, 93–102. doi: 10.1016/S0006-8993(02)00205-7

Radomska, N., Kaufmann, C., and Dreyer, C. (1999). Nuclear accumulation of S-adenosylhomocysteine hydrolyse in transcriptionally active cells during development of Xenopus laevis. Mol. Biol. Cell 10, 4283–4298. doi: 10.1091/mbc.10.12.4283

Reddy, M. C., Kuppan, G., Shetty, N. D., Owen, J. L., Ioerger, T. R., and Saccettini, J. C. (2008). Crystal structures of Mycobacterium tuberculosis S-adenosyl-L-homocysteine hydrolase from ternary complex with substrate and inhibitors. Structure 17, 404–417. doi: 10.1010/structure.2008.038332

Seo, H. C., and Ettinger, M. J. (1993a). Identification and purification of a self-associating copper-binding protein from mouse hepatic cytosol. J. Biol. Chem. 268, 1151–1159. doi: 10.1021/bi020408l

Richon, V. M., Johnston, D., Neerenderg, C. J., Jin, L., Majer, C. R., Elliston, K., et al. (2011). Chromatin analysis of human protein methyltransferases. Chem. Biol. Drug Des. 78, 199–210. doi: 10.1111/j.1747-0825.2011.01135.x

Rocha, P. S., Sheikh, M., Melchiorre, R., Fagard, M., Boutet, S., Loach, R., et al. (2005). The Arabidopsis homology-dependent gene silencing(1) gene codes for an S-adenosyl-L-homocysteine hydrolyse required for DNA methylation-dependent gene silencing. Plant Cell 17, 404–417. doi: 10.1105/tpc.104.028332

Shin, Y. S., Jarhad, D. B., Jang, M. H., Kovaickova, K., Kim, G., Yoon, J. S., et al. (2020). Identification of 6-beta-fluoro-homoasparticinomycotin a potent inhibitor of chikungunya virus replication. Eur. J. Med. Chem. 187, 111956. doi: 10.1016/j.ejmech.2019.111956

Seo, H. C., and Ettinger, M. J. (1993b). Purification and properties of a self-associating, 50-kDa copper-binding protein from brinded mouse livers. J. Biol. Chem. 268, 1160–1165. doi: 10.1021/bi020058f

Shino, Y. S., Jarhad, D. B., Jang, M. H., Kovaickova, K., Kim, G., Yoon, J. S., et al. (2020). Identification of 6-beta-fluoro-homoasparticinomycotin a potent inhibitor of chikungunya virus replication. Eur. J. Med. Chem. 187. doi: 10.1016/j.ejmed.2019.111956

Snoeck, R., Andrei, G., Neys, J., Schols, D., Cools, M., Balzarini, J., et al. (1993). Inhibitory activity of S-adenosylhomocysteine hydrolyse inhibitors against human cytomegalovirus replication. Antivir. Res. 21, 197–216. doi: 10.1016/0166-3542(93)90028-8

Stender, S., Chakrabarti, R. S., Xing, C., Gotway, G., Cohen, J. C., and Hobbs, H. H. (2015). Adult-onset liver disease and hepatocellular carcinoma in S-adenosylhomocysteine hydrolyse deficiency. Mol. Genet. Metab. 116, 269–274. doi: 10.1016/j.ymgme.2015.10.009

Stepkowski, T., Brzezinski, K., Legocki, A. B., Jaskolski, M., and Bena, G. (2005). Bayesian phylogenetic analysis reveals two-domain topology of S-adenosylhomocysteine hydrolyse protein sequences. Mol. Phylogenet. Evol. 34, 15–28. doi: 10.1016/j.ympev.2004.09.008

Strauss, K. A., Ferreira, C., Bottiglieri, T., Zhao, X., Arning, E., Zhang, S., et al. (2015). Liver transplantation for treatment of severe S-adenosylhomocysteine hydrolyse deficiency. Mol. Genet. Metab. 116, 44–52. doi: 10.1016/j.ymgme.2015.06.005

Tanaka, H., Masuta, C., Uehara, K., Kataoka, A., Koivai, A., and Noma, M. (1997). Morphological changes and hypomethylation of DNA in transgenic tobacco expressing antisense RNA of the S-adenosyl-L-homocysteine hydrolyse gene. Plant Mol. Biol. 35, 981–986.

Tanaka, N., Nakanishi, M., Kusakabe, Y., Shiraika, K., Yabe, S., Ito, Y., et al. (2004). Crystal structure of S-adenosyl-L-homocysteine hydrolyse from the human malaria parasite Plasmodium falciparum. J. Mol. Biol. 343, 1007–1017. doi: 10.1016/j.jmb.2004.08.104

Vizán et al. AHCY Function in Development and Disease
Tehlivets, O., Malanovic, N., Visram, M., Pavkovic-Keller, T., and Keller, W. (2013). S-adenosyl-L-homocysteine hydrolase and methylation disorders: yeast as a model system. Biochem. Biophys. Acta 1832, 204–215. doi: 10.1016/j.bbadis.2012.09.007

Turner, M. A., Yuan, C. S., Borchardt, R. T., Hershfield, M. S., Smith, G. D., and Howell, P. L. (1998). Structure determination of selenomethionyl S-adenosylhomocysteine hydrolase using data at a single wavelength. Nat. Struct. Biol. 5, 369–376. doi: 10.1038/nsb0598-369

Vivante, A., Iyel, H., Pode-Shakked, B., Chen, J., Shril, S., Van Der Ven, A. T., et al. (2017). Exome sequencing in Jewish and Arab patients with rhabdomyolysis reveals single-gene etiology in 43% of cases. Pediatr. Nephrol. 32, 2273–2282. doi: 10.1007/s00467-017-3755-8

Vugrek, O., Beluzic, R., Nakic, N., and Mudd, S. H. (2009). S-adenosylhomocysteine hydrolase (AHCY) deficiency: two novel mutations with lethal outcome. Hum. Mutat. 30, E555–E565.

Walsh, C. T., and Moore, B. S. (2019). Enzymatic cascade reactions in biosynthesis. Angew. Chem. Int. Ed. Engl. 58, 6846–6879. doi: 10.1002/anie.201807844

Wang, M., Borchardt, R. T., Schowen, R. L., and Kuczera, K. (2005). Domain motions and the open-to-closed conformational transition of an enzyme: a normal mode analysis of S-adenosyl-L-homocysteine hydrolase. Biochemistry 44, 7228–7239. doi: 10.1021/bi047524m

Wang, Y., Kavran, J. M., Chen, Z., Karukurichi, K. R., Leahy, D. J., and Cole, P. A. (2014). Regulation of S-adenosylhomocysteine hydrolase by lysine acetylation. J. Biol. Chem. 289, 31361–31372. doi: 10.1074/jbc.m114.597153

Wang, Z., Yip, L. Y., Lee, J. H. J., Wu, Z., Chew, H. Y., and Chong, P. K. W. (2019). Methionine is a metabolic dependency of tumor-initiating cells. Nat. Med. 25, 825–837.

Westermann, F., Muth, D., Benner, A., Bauer, T., Henrich, K. O., and Oberthuer, A. (2008). Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 9:R150.

Wu, X., Li, F., Kolenovsky, A., Caplan, A., Cui, Y., and Cutler, A. (2009). A mutant deficient in S-adenosylhomocysteine hydrolase in Arabidopsis shows defects in root-hair development this paper is one of a selection of papers published in a special issue from the national research council of canada – plant biotechnology institute. Botany 87, 571–584. doi: 10.1139/b08-124

Yang, X., Hu, Y., Yin, D. H., Turner, M. A., Wang, M., Borchardt, R. T., et al. (2003). Catalytic strategy of S-adenosyl-L-homocysteine hydrolase: transition-state stabilization and the avoidance of abortive reactions. Biochemistry 42, 1900–1909. doi: 10.1021/bi0262350

Ye, C., and Tu, B. P. (2018). Sink into the epigenome: histones as repositories that influence cellular metabolism. Trends Endocrinol. Metab. 29, 626–637. doi: 10.1016/j.tem.2018.06.002

Yee, N. S., Lorent, K., and Pack, M. (2005). Exocrine pancreas development in zebrafish. Dev. Biol. 284, 84–101. doi: 10.1016/j.ydbio.2005.04.035

Yin, D., Yang, X., Hu, Y., Kuczera, K., Schowen, R. L., Borchardt, R. T., et al. (2000). Substrate binding stabilizes S-adenosylhomocysteine hydrolase in a closed conformation. Biochemistry 39, 9811–9818. doi: 10.1021/bi000595a

Yoon, J. S., Kim, G., Jarhad, D. B., Kim, H. R., Shin, Y. S., and Qu, S. (2019). Design, synthesis, and Anti-RNA virus activity of 6'-fluorinated-aristeromycin analogues. J. Med. Chem. 62, 6346–6362. doi: 10.1021/acs.jmedchem.9b00781

Zhang, J., and Zheng, Y. G. (2016). SAM/SAH Analogs as versatile tools for SAM-dependent methyltransferases. ACS Chem. Biol. 11, 583–597. doi: 10.1021/acschembio.5b00912

Zhao, J. N., Wang, Y., Zhao, B. S., and Chen, L. L. (2009). Analyzing S-adenosylhomocysteine hydrolase gene sequences in deuterostome genomes. J. Biomol. Struct. Dyn. 27, 371–380. doi: 10.1080/07391102.2009.10507323

Zhao, Y., and Garcia, B. A. (2015). Comprehensive catalog of currently documented histone modifications. Cold Spring Harb. Perspect. Biol. 7:a025064. doi: 10.1101/cshperspect.a025064

Zhou, J., Yang, L., Zhong, T., Mueller, M., Men, Y., and Zhang, N. (2013). H19 IncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase. Nat. Commun. 6:10221.

Zhu, Q., Cheng, X., Cheng, Y., Chen, J., Xu, H., and Gao, Y. (2020). O-GlcNAcylation regulates the methionine cycle to promote pluripotency of stem cells. Proc. Natl. Acad. Sci. U. S. A. 117, 7755–7763. doi: 10.1073/pnas.1915582117

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Vizán, Di Croce and Aranda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.